Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Purchased by Swiss National Bank

Swiss National Bank boosted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 17.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,300 shares of the company’s stock after buying an additional 6,600 shares during the quarter. Swiss National Bank’s holdings in Apogee Therapeutics were worth $2,007,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in APGE. Wellington Management Group LLP raised its holdings in Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after acquiring an additional 1,267,451 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Apogee Therapeutics by 4,018.9% in the 3rd quarter. Janus Henderson Group PLC now owns 469,557 shares of the company’s stock valued at $27,586,000 after purchasing an additional 458,157 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after purchasing an additional 438,036 shares in the last quarter. Barclays PLC lifted its position in shares of Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after purchasing an additional 287,243 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of Apogee Therapeutics during the third quarter worth $8,018,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Insider Buying and Selling

In other news, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.58, for a total transaction of $608,700.00. Following the completion of the sale, the chief executive officer now owns 1,302,987 shares in the company, valued at $52,875,212.46. This represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90. Following the completion of the transaction, the insider now owns 255,348 shares in the company, valued at approximately $11,986,035.12. This trade represents a 1.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,195 shares of company stock worth $2,026,392 in the last 90 days. Company insiders own 36.10% of the company’s stock.

Analyst Ratings Changes

APGE has been the topic of a number of analyst reports. Citigroup began coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 price target on the stock. Wedbush restated an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $92.17.

Apogee Therapeutics Stock Up 1.2 %

Shares of NASDAQ APGE opened at $39.72 on Friday. The business has a 50-day moving average price of $37.57 and a 200 day moving average price of $46.00. The stock has a market cap of $1.79 billion, a PE ratio of -16.41 and a beta of 2.46. Apogee Therapeutics, Inc. has a 52-week low of $29.10 and a 52-week high of $68.21.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.